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Abstract
Background and Purpose
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopa-
thy (CADASIL), caused by mutations in the NOTCH3 gene, is the most common monogenic
disorder causing lacunar stroke and cerebral small vessel disease (SVD). Fabry disease
(FD) due to mutations in the GLA gene has been suggested as an underdiagnosed cause of
stroke, and one feature is SVD. Previous studies reported varying prevalence of CADASIL
and FD in stroke, likely due to varying subtypes studied; no studies have looked at a large
cohort of younger onset SVD. We determined the prevalence in a well-defined, MRI-verified
cohort of apparently sporadic patients with lacunar infarct.
Methods
Caucasian patients with lacunar infarction, aged70 years (mean age 56.7 (SD8.6)), were
recruited from 72 specialist stroke centres throughout the UK as part of the Young Lacunar
Stroke DNA Resource. Patients with a previously confirmed monogenic cause of stroke
were excluded. All MRI’s and clinical histories were reviewed centrally. Screening was per-
formed for NOTCH3 andGLAmutations.
Results
Of 994 subjects five had pathogenicNOTCH3mutations (R169C, R207C, R587C, C1222G
and C323S) all resulting in loss or gain of a cysteine in theNOTCH3 protein. All five patients
had confluent leukoaraiosis (Fazekas grade2). CADASIL prevalence overall was 0.5% (95%
CI 0.2%-1.1%) and among cases with confluent leukoaraiosis 1.5% (95%CI 0.6%-3.3%). No
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classic pathogenic FDmutations were found; one patient had a missensemutation (R118C),
associated with late-onset FD.
Conclusion
CADASIL cases are rare and only detected in SVD patients with confluent leukoaraiosis.
No definite FD cases were detected.
Background
Lacunar infarction, resulting from occlusion of the cerebral small vessels, accounts for a quarter
of all ischemic strokes. Family history studies support a role for genetic factors in the risk of
lacunar stroke [1, 2], and a number of monogenic cause of cerebral small vessel disease (SVD)
have been described. The most common of these is cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL), caused by mutations in the
NOTCH3 gene.
The main clinical symptoms of CADASIL are migraine with aura, lacunar strokes, progres-
sive cognitive deficits and depression [3]. Another monogenic disorder that causes SVD is
Fabry disease (FD), an X-linked lysosomal storage disorder, caused by mutations in the GLA
gene. The resulting alpha-galactosidase A deficiency causes accumulation of glycolipids in the
walls of small blood vessels, nerves, glomerular and tubular epithelial cells, and cardiomyocytes
[4]. Both lacunar stroke and radiological appearances of SVD on MRI have been described as a
feature of the disease [5].
It has been suggested both FD and CADASIL are underdiagnosed [6, 7]. Previous studies
reported a varying prevalence of CADASIL and FD in stroke [8–11], most likely due to varying
methods and phenotypes studied. Few studies have looked at the prevalence of these diseases
in large cohorts with apparently sporadic SVD. In addition, no studies have looked at a large
MRI-defined cohort of younger onset lacunar stroke.
We determined the prevalence of pathogenic NOTCH3 and GLAmutations in a large well-
defined, MRI verified cohort of patients with apparently sporadic lacunar stroke.
Methods
Study population
This study is a part of the Young Lacunar Stroke DNA study, a multicentre cohort study,
which constitutes a large DNA resource of young patients with well phenotyped lacunar stroke
and stroke-free community controls.
Between 2005 and 2012, 1247 patients with suspected lacunar stroke without a known
monogenic cause were recruited from 72 specialist stroke centres throughout the UK (S1
Table). Collection was as part of a single study with an identical study protocol, and identical
inclusion and exclusion criteria as well as a single data collection form used in all participating
centres. Inclusion criteria were age of stroke< 70 years, MRI confirmed lacunar stroke and
European ancestry.
Lacunar stroke was defined as a clinical lacunar syndrome [12], with a compatible lesion on
MRI (subcortical infarct15 mm in diameter). Patients had to have had a clinical MRI for
inclusion, and imaging of the carotid arteries and ECG was mandatory. Echocardiography was
performed when appropriate. All MRI’s and clinical histories were reviewed centrally in a
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single co-ordinating centre by one physician (HM). Exclusion criteria were: stenosis> 50% in
the extra- or intracranial cerebral vessels, or previous carotid endarterectomy; cardioembolic
source of stroke, defined according to the TOAST (Trial of Org 10172 in Acute Stroke Treat-
ment) criteria [13], as high or moderate probability; cortical infarct on MRI; subcortical
infarct> 15mm in diameter, as these can be caused by embolic mechanisms (striatocapsular
infarcts); any other specific cause of stroke (e.g. lupus anticoagulant, cerebral vasculitis, dissec-
tion) and known monogenic forms of stroke e.g. CADASIL). 1030 patients met the inclusion
criteria of the main study and 994 patients had DNA of sufficient quality available in which
screening for CADASIL and FD was performed. The study was approved by the Multi-Centre
Research Ethics Committee for Scotland (04/MRE00/36) and written informed consent was
obtained from all participants. Leukoaraiosis was graded on MRI using the semi-quantitative
Fazekas scale which has been shown to reflect pathological severity of SVD in a post-mortem
validation study [14]. All MRI’s and clinical histories were reviewed centrally by one physician
(HM). Patients were considered to have leukoaraiosis if they had a Fazekas grade ≧2. In addi-
tion in patients found to be CADASIL positive white matter hyperintensities in the anterior
temporal pole and the external capsule, characteristic locations for CADASIL, where graded
using the Scheltens scale [15]. Central review of all cases including MRIs was performed
blinded to the results of the genetic analysis.
Cardiovascular risk factors
Hypertension was defined as taking antihypertensive treatment or blood pressure greater than
160 mmHg systolic or 90mmHg or diastolic one week or more after acute stroke onset. Hyper-
cholesterolemia was defined as on drug treatment of cholesterol> 5.2mmol/l.
Genetic analysis
DNA was extracted and purified from whole blood (collected in EDTA) using the Nucleon
BACC3 genomic DNA extraction kit (Tepnel Life Sciences, Manchester, UK) or the Chemagic
Blood 3k DNA kit in conjunction with a Magnetic Separation Module 1 (PerkinElmer Chema-
gen Technologie GmbH, Baesweiler).
The NOTCH3 gene was screened by denaturing high performance liquid chromatography
(DHPLC) using the WAVE 3500HT system (Transgenomic Ltd., Glasgow, UK). Exons 3, 4 5,
6, 8, 11, 18, 19 and 22 were screened. This screen has been shown to detect 90% of mutations in
a UK population [16]. This was followed by Sanger sequencing of exons 3 and 4 in all cases and
sequencing of samples with a suspected variant in any other exon. Fragments were amplified
using polymerase chain reaction (PCR), cleaned up using Exonuclease and FastAP Thermosen-
sitive Alkaline Phosphatase (Thermo Scientific, UK), and sequenced using a BigDye Termina-
tor Cycle Sequencing kit (Perkin Elmer Applied Biosystems, Cheshire, UK) and analysed on an
ABI3100 sequencer (Applied Biosystems, Foster City, CA) according to the manufacturer's
instructions. Sequences were analysed using Sequencher 5.0 (Gene Codes, Ann Arbor, MI,
USA).
The GLA gene was screened using high resolution melt-curve analysis on an ABI7500 Fast
Real-Time PCR platform, using ABI HRMMastermix in 9 separate PCR reactions, covering all
exons, all intron/exon junctions and one specific reaction aimed at a common deep intronic
mutation. Primer sequences are found in a paper by Tai and colleagues.[17] Samples with a
suspected variant were sequenced on an ABI3500XL automated sequencer using ABI BigDye
v1.1. Prior to setting up the sequencing reaction, PCR products were cleaned up using ExoSap-
IT (Affymetrix, High Wycombe, UK) and excess dye terminators were removed using the
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DyeEx 96 system (Qiagen, Manchester, UK). Sequences were analysed using Mutation Sur-
veyor software (SoftGenetics, State College, PA, USA).
Nonsynonymous variants were evaluated for pathogenicity by in silicomutation prediction
tools, using three algorithms (PolyPhen-2 [18], SIFT [19] and Mutation Taster [20]).
Results
Patient characteristics are shown in Table 1. There were 617 patients (62.1%) with first stroke
onset at60 years. A history of stroke in first-degree relatives was reported in 427 patients
(43.0%).
Five patients had pathogenic NOTCH3mutations (c.505C>T, R169C; c.619C>T, R207C;
c.1759C>T, R587C; c.3664T>G, C1222G; c.967T>A, C323S) all resulting in loss or gain of a
cysteine in the NOTCH3 protein. Clinical characteristics of these five patients are reported in
Table 2. All five cases had confluent leukoaraiosis, but there were few non-stroke clinical fea-
tures of CADASIL (Fig 1). Only two had migraine and both of these were migraine without
aura. Three cases had no family history of stroke. On MRI review three cases had no anterior
temporal pole involvement, while it was mild (Schelten’s grades 1 and 2) in the other two cases.
The overall mutation carrier frequency was 0.5% (95% CI 0.2%-1.1%), while among cases
with confluent leukoaraiosis it was 1.5% (95% CI 0.6%-3.3%). Comparing age groups, the over-
all mutation carrier frequency was 0.6% (95% CI 0.2%-1.6%) in patients aged 60 years and
0.3% (95% CI 0.01%-1.3%) in patients aged>60 years. Among cases with confluent leukoar-
aiosis the mutation carrier frequency was 1.9% (95% CI 0.5%-5.0%) in patients aged 60 years
and 0.6% (95% CI 0.03%-2.9%) in patients aged>60 years.
In addition to the reported pathogenic mutations, two novel NOTCH3missense variants
(c.319C>T, R107W and c.3552C>G, D1184E) were identified that do not disrupt the number
of cysteine residues in any EGF-like domains. However, both novel missense mutations were
predicted by Polyphen2 as probably damaging, SIFT predicted only R107W to affect protein
function and MutationTaster predicted only D1184E to be pathogenic. Clinical characteristics
of these two patients are reported in Table 3.
Table 1. Patient characteristics.
Age, mean years (SD) 56.7 (8.6)
Male, n (%) 706 (71.0)
Hypertension, n (%) 714 (71.8)
Diabetes, n (%) 165 (16.6)
Hypercholesterolemia, n (%) 671 (67.7)
Ever smoker, n (%) 698 (70.2)
Alcohol  20 u/week 290 (29.2)
BMI, mean kg/m2 (SD) 28.7 (6.2)
Migraine, n (%) 195 (19.6)
MI, n (%) 35 (3.5)
PVD, n (%) 28 (2.8)
Recurrent strokes, n (%) 77 (7.7)
Leukoaraiosis (Fazekas grade 2), n (%) 329 (33.1)
Number of lacunes, median (IQR) 2 (1–2)
Microbleeds presenta, n (%) 63 (18.6)
Abbreviations: SD: standard deviation; IQR: interquartile range.
a Gradient echo imaging was available in 339 (34%) patients.
doi:10.1371/journal.pone.0136352.t001
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None of the patients had a nonsense mutation in the GLA gene known to cause classical FD.
One missense mutation (c.352C>T, R118C) was identified, which has been suggested to be a
mild or late-onset variant [7, 21]. Clinical characteristics of this patient are reported in Table 3
and Fig 2 shows the corresponding brain MRI.
Discussion
We present the results of a comprehensive screening study of the NOTCH3 gene for CADASIL
and the GLA gene for FD in a large cohort of MRI confirmed young lacunar stroke. A few cases
of CADASIL were detected giving an overall prevalence of 0.5%, although this rose to 1.5%
when only patients with confluent leukoaraiosis were considered. We found only one case of a
GLAmutation possibly associated with Fabry disease.
Only a few studies have investigated the prevalence of CADASIL in unselected ischemic
stroke patients [8, 9, 11]. The reported prevalence in these studies varied between 0% and 4%,
which is probably due to the phenotypic variation and small numbers. In the current study we
reduced the phenotypic variation by investigating a large sample of patients with MRI-defined
lacunar stroke, which is the typical stroke subtype in CADASIL patients.
Our findings are in line with the mutation frequency reported in a much smaller previous
study.[9] The CADASIL mutations were typical point mutations resulting in a loss or gain of a
cysteine residue in an EGF-like repeat. Two were novel (C1222G and C323S) while R169C and
R207C have been previously described in Caucasian CADASIL patients [22, 23], whereas the
R587C mutation only has been reported in a Korean CADASIL patient [24]. The cases
Table 2. Characteristics of patients with aNOTCH3mutation.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Mutation R169C C1222G R207C R587C C323S
Demographics and vascular risk factors
Age at ﬁrst stroke (years) 45 55 58 65 34
Sex Male Male Male Female Male
Hypertension No Yes Yes Yes No
Diabetes No Yes No No No
Hyperlipidaemia Yes Yes Yes Yes Yes
Ever smoker Yes Yes Yes Yes Yes
Alcohol  20 units/week No No No No Yes
Body mass index (kg/m2) 30 26 25 27 22
Depression No No No No No
Migraine Yes, no aura No Yes, no aura No No
Myocardial infarction No No No No No
Peripheral vascular disease No No No No No
Recurrent strokes No Yes Yes No No
Family history of stroke Father, age 36 No Mother, age 70 No No
Brain MRI characteristics
Leukoaraiosis (Fazekas grade, 1–3) 3 2 3 3 2
Number of lacunes 3 3 2 1 2
Microbleeds NA No NA No No
Anterior temporal pole WMH (Scheltens scale, 1–6) 1 0 0 0 2
External capsule WMH (Scheltens scale, 1–6) 5 0 3 6 0
Abbreviations: WMH, white matter hyperintensities; NA, not available.
doi:10.1371/journal.pone.0136352.t002
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identified in the current study had few non-stroke clinical or MRI features of CADASIL. An
explanation for this is that any cases with obvious characteristics of CADASIL would have
been excluded, as an exclusion criteria was a diagnosis of CADASIL at presentation. Further-
more, traditional cardiovascular risk factors were common in these patients, which might have
led to lack of suspicion.
In addition, two novel variants were found (R107W and D1184E), also located in one of the
EGF-like repeats, but not involving any cysteine residues. Although in silicomutation predic-
tion tools predicted these mutations to be probably pathogenic, functional studies are needed
to confirm this pathogenicity. Other non-cysteine affecting NOTCH3mutations have been
described in SVD, although their pathogenicity has been debated [25–27].
A potential limitation of the current study is that not all of the exons encoding the extracel-
lular portion of the Notch 3 protein in which CADASIL mutations occur were screened. How-
ever, it has been shown that mutations in the NOTCH3 exons screened in this study (3–6, 8,
11, 18, 19, and 22) account for 90% of CADASIL mutations in the UK population in which this
study was performed [16, 22, 28].
Fig 1. FLAIR Brain MRIs scans from two of the patients with notch 3 mutations. The upper panel 1 shows images from patient 1 (R169C), and the lower
panel two shows images from patient 2 panel 2 (C1222G). These show leukoaraiosis in both cases (images C and D) but minimal anterior pole involvement
in patient 1 (image upper panel A) and no involvement in patient 2 (image lower panel A). Patient 1 also shows confluent external capsule involvement
(image B), but this is absent from patient 4 (lower panel B).
doi:10.1371/journal.pone.0136352.g001
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A study in young-onset cryptogenic stroke patients reported a prevalence of FD as high as
4.9% in males and 2.4% in females [29], although subsequent studies in young onset stroke
patients have found lower prevalence (0%-2.4% in cryptogenic stroke and 0%-1% in all ische-
mic stroke) [21, 30–36]. Although FD is associated with a number of stroke mechanisms
including cardioembolism, and disease of the vertebrobasilar arteries, small vessel disease is a
recognized feature and white matter hyperintensities on MRI are common [5]. No previous
studies have investigated the prevalence of FD in large cohorts of MRI defined lacunar stroke.
Table 3. Clinical characteristics of cases with genetic variants of unknown significance.
Patient 5 Patient 6 Patient 7
Gene NOTCH3 NOTCH3 GLA
Mutation R107W D1184E R118C
Age at event (years) 63 58 56
Sex Male Female Male
Hypertension Yes Yes Yes
Diabetes No Yes Yes
Hyperlipidaemia No Yes Yes
Ever smoker Yes Yes Yes
Alcohol  20 u/week No No No
Body mass index, (kg/m2) 32 36 27
Depression No No No
Migraine No No No
Myocardial infarction No No Yes
Peripheral vascular disease No No No
Renal function Normal Normal Normal
Recurrent strokes No No Yes
Family history of stroke Mother, age unknown Two siblings, ages 47 & 56 Mother, age 61
Leukoaraiosis (Fazekas grade 2) No Yes No
doi:10.1371/journal.pone.0136352.t003
Fig 2. Brain MRI (T2-Weighted) of the patient carrying theGLAmutation R118C. Two lacunes are present in the right caudate nucleus and external
capsule (C). An area of white matter hyperintensity is present in the peripheral right posterior frontal white matter (D). There were no abnormalities in the
posterior circulation.
doi:10.1371/journal.pone.0136352.g002
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We found only one missense mutation in the GLA gene (R118C); it is unclear if this was related
to FD but an association late onset FD has been previously suggested [7, 21]. In contrast to
mutations causing classical FD, R118C is associated with relatively high residual α-galactosi-
dase-A activity, lack of accumulation of lyso-Gb3 and carriers exhibit few symptoms that
might be suggestive of FD [7, 21, 37]. Because testing was performed on stored blood samples
on an anonymous basis, we were not able to carry further tests on the patient to confirm the
diagnosis. Despite FD being an X-linked disease, cases of stroke due to GLAmutations have
been described in women as well as men. However, in women accurate diagnosis cannot be
made by blood activity of alpha-galactosidase A, and therefore we performed genotyping for
causative mutations in both genders. Although the yield of FD screening seems to be low in
lacunar stroke patients, the yield of FD screening may be higher in other stroke populations.
Small vessel disease is only one of the stroke subtypes associated with Fabry disease and other
presentation include cardioembolism and otherwise cryptogenic stroke. It is possible that the
yield of Fabry screening may be higher in other groups of young stroke patients including
patients with cryptogenic stroke, or in patients who have signs of systemic disease such as renal
disease.
In conclusion we aimed to provide an estimate of the prevalence of mutations causing
CADASIL and FD in a large British cohort of patients presenting with apparently sporadic
lacunar stroke. Our study suggests that CADASIL is only present in patients with leukoaraiosis,
in whom the prevalence was 1.5%. The CADASIL patients that were detected in the present
study had conventional risk factors and not a MRI scan typical for CADASIL, which might
have led to lack of suspicion at presentation. Therefore, the presence of conventional risk fac-
tors and the absence of typical CADASIL characteristics on MRI should not necessarily pre-
clude screening in younger onset lacunar stroke patients, particularly if there is confluent
leukoaraiosis. Screening for FD has a very low pick up in this patient group.
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